The Philippines represents one of the most dynamic pharmaceutical markets in Southeast Asia. With the implementation of the Universal Health Care (UHC) Act, there is an unprecedented surge in demand for affordable, high-quality generic medicines and nutritional supplements. As a leading APIs & Intermediates supplier, Jiangxi Serum Pharma understands that the local industry is transitioning from simple drug distribution to more complex local manufacturing and formulation.
Currently, the Philippine market is heavily reliant on imported Active Pharmaceutical Ingredients (APIs). This creates a strategic opportunity for suppliers who can provide not just raw materials, but Information Gain—technical dossiers, stability data, and regulatory support that align with the Philippine Food and Drug Administration (PFDA) requirements.
Global pharmaceutical supply chains are shifting towards "China + 1" strategies. For the Philippines, this means establishing robust partnerships with Chinese manufacturers who offer GMP-certified facilities and transparent supply chains to ensure national drug security.
From the bustling labs in Quezon City to the manufacturing hubs in Laguna, our APIs are used in chronic disease management (Diabetes, Hypertension) and the rapidly growing "functional beverage" sector in Metro Manila.
Navigating the PFDA's Administrative Order No. 2013-0022 requires precision. We provide full documentation support, including Certificate of Analysis (COA) and MSDS, ensuring seamless customs clearance at the Port of Manila.
Jiangxi Serum Pharma Industries Co., Ltd. is a professional supplier of pharmaceutical and nutritional products. For nearly 10 years, we have been dedicated to exporting biological products, vaccines, Western medicines, raw materials, intermediates, medical consumables, food additives, and plant extracts.
We are not just moving boxes; we are advancing science. Our roadmap for the Philippine market focuses on three core technological pillars:
Customized nutrient and API pre-mixes that reduce manufacturing complexity for local Filipino laboratories, ensuring dosage uniformity and reducing production costs.
Enhancing the solubility and bioavailability of poorly water-soluble drugs, a critical factor for the tropical climate of the Philippines where stability is paramount.
Leveraging sustainable biological processes to produce high-purity peptides and proteins, catering to the growing Halal-conscious demographic in Mindanao.
The Philippines pharmaceutical market (worth approx. USD 4.5 Billion) is unique. Our local support and compliance guarantee ensure that every batch of Intermediates or APIs meets the specific monograph standards required by your quality control teams.
Exploring the potential of plant-based squalene in the Philippine cosmetic and pharmaceutical industry as a sustainable alternative to shark-derived oils.
Why this critical molecule remains a staple in Philippine hospital settings for managing inflammatory conditions and respiratory distress.
The rise of oral small-molecule GLP1 drugs and their projected impact on the metabolic health sector in Southeast Asia.
Yes, we provide comprehensive technical dossiers and Open-Part DMFs to support our Philippine clients during their CPR (Certificate of Product Registration) applications with the PFDA.
Standard sea freight from Shanghai or Shenzhen to Manila takes approximately 7-10 days. For urgent API requirements, air freight can deliver to NAIA within 3-4 days.
Our APIs and Intermediates are manufactured to meet USP, BP, or EP standards. Each shipment is accompanied by a detailed Certificate of Analysis (COA) confirming compliance.
We use double-layered vacuum-sealed medical-grade plastic liners inside fiber drums or aluminum foil bags to ensure zero moisture ingress during transit and local storage.
Ensure your supply chain remains resilient, compliant, and cost-effective. Contact our specialized Philippines support team today.
